John Desjarlais Sells 4,118 Shares of Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) VP John Desjarlais sold 4,118 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $46,327.50. Following the sale, the vice president directly owned 266,333 shares of the company’s stock, valued at $2,996,246.25. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Xencor Stock Up 4.9%

Shares of XNCR stock traded up $0.55 during trading on Monday, reaching $11.87. The company’s stock had a trading volume of 835,908 shares, compared to its average volume of 711,120. The company has a market capitalization of $870.55 million, a price-to-earnings ratio of -9.57 and a beta of 0.95. Xencor, Inc. has a 1-year low of $6.92 and a 1-year high of $18.69. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25. The stock’s 50-day moving average price is $12.79 and its 200 day moving average price is $13.00.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The business had revenue of $28.24 million for the quarter, compared to the consensus estimate of $29.97 million. During the same quarter in the prior year, the business posted ($0.62) EPS. The business’s revenue for the quarter was down 46.6% on a year-over-year basis. On average, research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on XNCR. Wall Street Zen cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a report on Monday, December 29th. Barclays upped their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Finally, Truist Financial began coverage on Xencor in a research note on Monday, November 24th. They set a “buy” rating and a $29.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Xencor presently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Institutional Investors Weigh In On Xencor

A number of hedge funds have recently added to or reduced their stakes in XNCR. Hantz Financial Services Inc. grew its position in Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 2,156 shares during the last quarter. GAMMA Investing LLC boosted its position in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,449 shares during the period. Farther Finance Advisors LLC bought a new position in Xencor in the 3rd quarter valued at about $44,000. Federated Hermes Inc. raised its position in shares of Xencor by 114.3% during the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 2,105 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in shares of Xencor by 85.5% in the third quarter. Nisa Investment Advisors LLC now owns 5,260 shares of the biopharmaceutical company’s stock valued at $62,000 after acquiring an additional 2,424 shares in the last quarter.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.